Literature DB >> 23682303

Metastatic castration-resistant prostate cancer: The emerging continuum of care.

Fred Saad1.   

Abstract

Entities:  

Year:  2013        PMID: 23682303      PMCID: PMC3652213          DOI: 10.5489/cuaj.229

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  7 in total

1.  Guidelines for the management of castrate-resistant prostate cancer.

Authors:  Fred Saad; Sebastien J Hotte
Journal:  Can Urol Assoc J       Date:  2010-12       Impact factor: 1.862

2.  Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: Questions of choice.

Authors:  Jamil Asselah; Catherine Sperlich
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

3.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

4.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

5.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

6.  Optimal management of patients receiving cabazitaxel-based chemotherapy.

Authors:  Catherine Sperlich; Fred Saad
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

7.  Chemotherapy for prostate cancer: Clinical practice in Canada.

Authors:  Fred Saad; Jamil Asselah
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.